Von der Schilddrüsen-Szintigraphie zur In-vivo-Darstellung der Signaltransduktions-kaskade und darüber hinaus

T. Kuwert; O. Schober

doi:10.1055/s-0038-1629774

Nuklearmedizin - NuclearMedicine, Table of Contents

Nuklearmedizin 1996; 35(06): 1-2
DOI: 10.1055/s-0038-1629774

Editorial

Schattauer GmbH

Von der Schilddrüsen-Szintigraphie zur In-vivo-Darstellung der Signaltransduktions-kaskade und darüber hinaus^[*]

T. Kuwert

¹Klinik und Poliklinik für Nuklearmedizin (Dir.: Prof. Dr. Dr. O. Schober) Westfälische Wilhelms-Universität Münster, Deutschland

,

O. Schober

¹Klinik und Poliklinik für Nuklearmedizin (Dir.: Prof. Dr. Dr. O. Schober) Westfälische Wilhelms-Universität Münster, Deutschland

› Author Affiliations

Abstract

Full Text

References

Literatur
1 Baer FM, Voth E, Schneider CA. et al. Comparison of low dose dobutamine-gradient-echo magnetic resonance imaging and positron emission tomography with [¹⁸F]fluorodeoxyglucose in patients with chronic coronary artery disease. A functional and morphological approach to the detection of residual myocardial viability. Circulation 1995; 91: 1006-15.
2 Haque T, Furukawa T, Takahashi M. et al. Identification of hibernating myocardium by dobutamine stress echocardiography: comparison with thallium-201 reinjection imaging. Am Heart J 1995; 130: 553-63.
3 Hundley WG, Lange RA, Clarke GD. et al. Assessment of coronary arterial flow and flow reserve in humans with magnetic resonance imaging. Circulation 1996; 93: 1502-8.
4 Stöcklin G. Tracers for metabolic imaging of brain and heart: radiochemistry and radio-pharmacy. Eur J Nucl Med 1992; 19: 527-51.
5 Saha GB, Maclntyre WJ, Go RT. Radiopharmaceuticals for brain imaging. Semin Nucl Med 1994; 24: 324-49.
6 Playford ED, Brooks DJ. In vivo and in vitro studies of the dopaminergic system in movement disorders. Cerebrovasc Brain Metabol Rev 1992; 4: 144-71.
7 Schwarz J, Tatsch K, Arnold G. et al. Iodine-123-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with “de novo” parkinsonism. Neurology 1992; 42: 556-61.
8 Volkow ND, Fowler JS, Gatley SJ. et al. PET Evaluation of the dopamine system of the human brain. J Nucl Med 1996; 37: 1242-56.
9 Savic I, Persson A, Roland P. et al. In-vivo demonstration of reduced benzodiazepine receptor in human epileptic foci. Lancet 1988; 2: 864-6.
10 Bartenstein P, Ludolph A, Schober O. et al. Benzodiazepine receptors and cerebral blood flow in partial epilepsy. Eur J Nucl Med 1991; 18: 111-8.
11 Kuwert T, Stodieck SRG, Puskäs C. et al. Reduced GABA_A receptor density contralateral to a potentially epileptogenic MRI abnormality in a patient with complex partial seizures. Eur J Nucl Med 1996; 23: 95-8.
12 Schubiger PA, Hasler PH, Beer-Wohlfahrt H. et al. Evaluation of a multicenter study with iomazenil – a benzodiazepine receptor. Nucl Med Commun 1991; 12: 569-82.
13 Schwaiger M, Kalff V, Rosenspire K. et al. Noninvasive evaluation of sympathetic nervous system in human heart by positron emission tomography. Circulation 1990; 82: 457-64.
14 Merlet P, Delforge J, Syrota A. et al. Positron emission tomography with ^UC CGP-12177 to assess ß-adrenergic receptor concentration in idiopathic dilated cardiomyopathy. Circulation 1993; 87: 1169-78.
15 Böhm M, Schwinger RH, Erdmann E. Adrenergic beta receptors and guanine nucleotide binding proteins (G-proteins) of the failing human heart. Z Kardiol 1992; 81 Suppl4: 23-31.
16 Pfeffer MA, Stevenson LW. ß-Adrenergic blockers and survival in heart failure (editorial). New Engl J Med 1996; 334: 1396-7.
17 Wichter T, Hindricks G, Lerch H. et al. Regional myocardial sympathetic dysinnerva-tion in arrhythmogenic right ventricular cardiomyopathy. An analysis using ¹²³I-meta-iodobenzylguanidine scintigraphy. Circulation 1994; 89: 667-83.
18 Lerch H, Schäfers M, Wichter T. et al. Global reduction in post-, but not presynaptic cardiac adrenergic activity in patients with arrhythmogenic right ventricular disease (abstract). J Nucl Med 1996; 37 Supplement: 106P-97P.
19 Martiat Ph, Ferrant A, Labar D. et al. In vivo measurement of ^uC-thymidine uptake in non-Hodgkin’s lymphoma using positron emission tomography. J Nucl Med 1988; 29: 1633-7.
20 Goethals P, van Eijkeren M, Lodewyck W, Dams R. Measurement of [methyl-car-bon-ll]thymidine and its metabolites in head and neck tumors. J Nucl Med 1995; 36: 880-2.
21 Hildebrandt M, Reske SN. Voraussetzungen für den Einsatz von Antisense-Diagnostika in der Nuklearmedizin. Nuklearmedizin 1996; 35: 126-31.
22 Takahashi T, Ido T, Ootake A. et al. [¹⁸F] labeled 1,2-diacyglycerols; a new tracer for the imaging of second messenger system (abstract). J Labeled Compds Radiopharm 1994; 35: 517-9.
23 Imahori Y, Fujii R, Ueda S. et al. Phospho-inositide turnover imaging linked to muscarinic cholinergic receptor in the central nervous system by positron emission tomography. J Nucl Med 1993; 34: 1543-51.
24 Paschke R. Konstitutiv aktivierende Mutationen des TSH-Rezeptors als Hyperthyreo-seursache – Pathophysiologische und diagnostische Bedeutung. Deutsches Ärzteblatt 1995; 92: B-1948-B-52.
25 Feinendegen LE, Vyska K, Freundlieb C, Höck A, Machulla HJ, Kloster G, Stöcklin G. Non-invasive analysis of metabolic reactions in body tissues, the case of myocardial fatty acids. Eur J Nucl Med 1981; 6: 191-200.

Von der Schilddrüsen-Szintigraphie zur In-vivo-Darstellung der Signaltransduktions-kaskade und darüber hinaus[*]

Von der Schilddrüsen-Szintigraphie zur In-vivo-Darstellung der Signaltransduktions-kaskade und darüber hinaus^[*]